NPT 200 11

Drug Profile

NPT 200 11

Alternative Names: NPT200-11; UCB-1332

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuropore Therapies
  • Developer Neuropore Therapies; UCB
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 20 Sep 2016 Phase-I clinical trials in Multiple system atrophy in USA (unspecified route) before September 2016 (Neuropore pipeline, September 2016)
  • 01 Feb 2016 Neuropore Therapies completes a phase I trial in Parkinson's disease (In volunteers) in USA (PO) (NCT02606682)
  • 12 Aug 2015 Phase-I clinical trials in Parkinson's disease (In volunteers) in USA (PO) (NCT02606682)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top